Maat Pharma SA (MAAT) - Net Assets

Latest as of June 2025: €8.29 Million EUR ≈ $9.70 Million USD

Based on the latest financial reports, Maat Pharma SA (MAAT) has net assets worth €8.29 Million EUR (≈ $9.70 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€48.88 Million ≈ $57.14 Million USD) and total liabilities (€40.58 Million ≈ $47.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Maat Pharma SA (MAAT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€8.29 Million
% of Total Assets	16.97%
Annual Growth Rate	10.11%
5-Year Change	-35.14%
10-Year Change	N/A
Growth Volatility	184.15

Maat Pharma SA - Net Assets Trend (2017–2024)

This chart illustrates how Maat Pharma SA's net assets have evolved over time, based on quarterly financial data. Also explore MAAT total asset value for the complete picture of this company's asset base.

Annual Net Assets for Maat Pharma SA (2017–2024)

The table below shows the annual net assets of Maat Pharma SA from 2017 to 2024. For live valuation and market cap data, see MAAT market cap.

Year	Net Assets	Change
2024-12-31	€10.34 Million ≈ $12.08 Million	-49.50%
2023-12-31	€20.47 Million ≈ $23.93 Million	-23.67%
2022-12-31	€26.81 Million ≈ $31.34 Million	-32.73%
2021-12-31	€39.86 Million ≈ $46.60 Million	+150.08%
2020-12-31	€15.94 Million ≈ $18.63 Million	+449.11%
2019-12-31	€-4.57 Million ≈ $-5.34 Million	-459.73%
2018-12-31	€1.27 Million ≈ $1.48 Million	-75.91%
2017-12-31	€5.27 Million ≈ $6.16 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Maat Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1930413900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	€1.40 Million	13.53%
Other Components	€35.24 Million	340.96%
Total Equity	€10.34 Million	100.00%

Maat Pharma SA Competitors by Market Cap

The table below lists competitors of Maat Pharma SA ranked by their market capitalization.

Company	Market Cap
Pelthos Therapeutics Inc. NYSE MKT:PTHS	$75.77 Million
Sypris Solutions Inc NASDAQ:SYPR	$75.77 Million
Vow ASA OL:VOW	$75.79 Million
Panelsan Cati Cephe Sistemleri Sanayi ve Ticaret AS IS:PNLSN	$75.79 Million
Aldoro Resources Ltd AU:ARN	$75.76 Million
Shandong Zhonglu Oceanic Fisheries Co Ltd SHE:200992	$75.74 Million
Mitchell Services Ltd AU:MSV	$75.74 Million
Hwacheon Machi KO:010660	$75.74 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Maat Pharma SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 20,466,000 to 10,336,000, a change of -10,130,000 (-49.5%).
Net loss of 28,904,000 reduced equity.
Share repurchases of 17,258,000 reduced equity.
New share issuances of 17,276,000 increased equity.
Other factors increased equity by 18,756,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-28.90 Million	-279.64%
Share Repurchases	€17.26 Million	-166.97%
Share Issuances	€17.28 Million	+167.14%
Other Changes	€18.76 Million	+181.46%
Total Change	€-	-49.50%

Book Value vs Market Value Analysis

This analysis compares Maat Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 7.39x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 1.15x to 7.39x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€5.10	€5.85	x
2018-12-31	€1.23	€5.85	x
2019-12-31	€-22.11	€5.85	x
2020-12-31	€77.19	€5.85	x
2021-12-31	€16.43	€5.85	x
2022-12-31	€2.71	€5.85	x
2023-12-31	€1.80	€5.85	x
2024-12-31	€0.79	€5.85	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Maat Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -279.64%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -898.76%
• Asset Turnover: 0.08x
• Equity Multiplier: 3.72x
Recent ROE (-279.64%) is below the historical average (-114.35%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	-73.24%	-3529.47%	0.01x	1.76x	€-4.39 Million
2018	-358.23%	-509.64%	0.15x	4.64x	€-4.67 Million
2019	0.00%	-7443.12%	0.01x	0.00x	€-6.19 Million
2020	-33.57%	0.00%	0.00x	1.52x	€-6.94 Million
2021	-22.63%	-927.88%	0.02x	1.24x	€-13.00 Million
2022	-51.15%	-958.95%	0.03x	1.67x	€-16.39 Million
2023	-96.34%	-884.96%	0.05x	2.10x	€-21.76 Million
2024	-279.64%	-898.76%	0.08x	3.72x	€-29.94 Million

Industry Comparison

This section compares Maat Pharma SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $54,195,048
Average return on equity (ROE) among peers: -104.02%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Maat Pharma SA (MAAT)	€8.29 Million	-73.24%	4.89x	$75.76 Million
Abionyx Pharma SA (ABNX)	$7.42 Million	-59.27%	0.81x	$123.48 Million
Abivax SA (ABVX)	$11.78 Million	-260.03%	3.39x	$6.97 Billion
Adocia (ADOC)	$45.85 Million	16.61%	0.53x	$111.73 Million
Aelis Farma SA (AELIS)	$1.20 Million	-263.37%	5.00x	$18.95 Million
Biophytis S.A. (ALBPS)	$6.83 Million	-373.49%	2.98x	$1.03 Million
Cellectis (ALCLS)	$450.27 Million	-17.48%	0.11x	$282.27 Million
Advicenne (ALDVI)	$16.92 Million	-83.89%	0.35x	$21.67 Million
Genoway (ALGEN)	$1.90 Million	0.00%	1.85x	$30.11 Million
Integragen (ALINT)	$2.19 Million	0.70%	3.39x	$1.00 Million
Medesis Pharma SA (ALMDP)	$-2.42 Million	0.00%	0.00x	$1.80 Million

About Maat Pharma SA

PA:MAAT France Biotechnology

Market Cap

$128.25 Million

€109.70 Million EUR

Market Cap Rank

#20262 Global

#315 in France

Share Price

€5.85

Change (1 day)

+1.04%

52-Week Range

€3.65 - €7.78

All Time High

€13.95